Loading...
XETR
MDG1
Market cap22mUSD
Jan 22, Last price  
1.35EUR
Name

Medigene AG

Chart & performance

D1W1MN
XETR:MDG1 chart
P/E
—
P/S
3.30
EPS
—
Vol. 1Y
—
Shs. 5Y
0.74%
Rev. 5Y
-4.89%
Div Yld LY
—
Div Yld TTM
—
Revenues
6m
-80.69%
12,501,00019,555,00030,549,00022,058,00033,507,00037,859,0002,214,0002,300,0005,869,0007,548,00012,581,0003,101,0004,101,0007,676,0007,576,00010,511,0008,002,00010,463,00031,247,0006,034,000
Net income
-16m
L+94.20%
-12,666,000-12,045,000-6,891,000-29,876,000-30,790,000-21,962,000-17,869,0006,281,000-14,877,000-10,282,000-5,757,000-12,999,000-9,492,000-13,573,000-21,226,000-19,962,000-28,875,000-9,983,000-8,330,000-16,177,000
CFO
-15m
L
-12,096,000-10,437,000-1,330,000-32,100,000-25,856,000-18,801,000-11,411,0006,864,000-6,507,000-12,246,000-8,756,000-10,605,000-3,758,000-20,849,000-10,142,000-16,423,000-24,786,000-10,754,00011,976,000-15,119,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Medigene AG is a biotechnology firm dedicated to pioneering T cell immunotherapies aimed at combating cancer. Its primary therapeutic thrust involves personalized T cell-based treatments, specifically T cell receptor-modified T cells, which are currently undergoing clinical trials to address significant unmet medical needs. Beyond this core focus, Medigene also explores dendritic cell vaccines and specialized T cell monoclonal antibodies. Diverging from oncology, the company is additionally engaged in the development and commercialization of RhuDex for applications in hepatology and gastroenterology. Collaborations are key to Medigene's strategy; it maintains a strategic alliance with 2seventy bio, Inc. for advancing T cell receptor research. Furthermore, research cooperation agreements are in place with the Université de Montréal and Cytovant Sciences Co. Ltd. to discover and develop novel cancer antigens for immunotherapy. Established in 1994, the company's headquarters are located in Munich, Germany, with its operational footprint spanning Europe, the United States, Asia, and other international regions.

Key people

Horst Domdey
Chairman of the Supervisory Board · since 2013
Dolores J. Schendel
Chairman of the Executive Management Board, Chief Executive Officer, Chief Scientific Officer · since 2016
Axel-Sven Malkomes
Chief Financial Officer and Chief Business Development Officer · since 2019
Kai Pinkernell
Member of the Executive Management Board, Chief Medical Officer, Chief Development Officer · since 2018
URL
https://www.medigene.de/
IPO date
Jun 30, 2000
Employees
87
Domiciled in
DE
Incorporated in
DE
Headquarters & legal address
Lochhamer Straße 11
Planegg 82152
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT